Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid) is a research-grade, high-purity agonist for HM74A/GPR109A and GPR109B receptors, produced by APExBIO (product page). It enables precise interrogation of lipid metabolism pathways via selective G-protein coupled receptor (GPCR) modulation (Ye et al., 2025). Cryo-EM structural studies have validated its binding and selectivity for HCAR3 (GPR109B) and HCAR2 (GPR109A) under defined conditions. Acifran is supplied as an off-white solid (purity ≥98.00%) and is intended strictly for preclinical research. Storage at -20°C and prompt use of solutions are critical for maintaining activity (APExBIO).

Biological Rationale

Hydroxycarboxylic acid receptors (HCAR2/GPR109A and HCAR3/GPR109B) are GPCRs that play central roles in regulating lipid metabolism and energy homeostasis (Ye et al., 2025). HCAR2 is a validated target for dyslipidemia therapy, while HCAR3 is emerging as a distinct modulator with a different side effect profile. Acifran’s high selectivity for these receptors makes it an indispensable tool for dissecting the molecular mechanisms underpinning lipid signaling and metabolic disorders (precisionfda.org). This article extends previous overviews by integrating recent structural data, clarifying Acifran’s binding specificity, and providing practical workflow parameters for laboratory settings.

Mechanism of Action of Acifran

Acifran acts as a selective agonist of HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) by binding to the orthosteric ligand-binding pocket of these GPCRs. Structural studies using cryo-EM have resolved the acifran-HCAR3-Gi1 complex at 3.18 Å and the acifran-HCAR2-Gi1 complex at 2.72 Å resolution (Ye et al., 2025). The selectivity for HCAR3 over HCAR2 is attributed to π–π stacking interactions with F1073.32 and differences in pocket residues (V/L832.60, Y/N862.63, S/W9123.48). Upon agonist binding, a conformational change enables Gi protein coupling and downstream inhibition of cAMP production in target cells (Ye et al., 2025).

Evidence & Benchmarks

• Acifran binds the HCAR3-Gi1 complex with a resolved structure at 3.18 Å (cryo-EM), confirming direct interaction and selectivity (Ye et al., 2025).
• Acifran activates HCAR2 (GPR109A) and HCAR3 (GPR109B) in cAMP inhibition assays in HEK-293 cells, demonstrating functional agonism under physiologic buffer conditions (Ye et al., 2025).
• The compound exhibits less than 21.82 mg/ml solubility in ethanol and DMSO at room temperature, supporting compatibility with common assay solvents (APExBIO).
• Supplied at ≥98.00% purity, Acifran ensures reproducibility in bench experiments (APExBIO).
• Cryo-EM density maps and atomic coordinates for acifran-receptor complexes are publicly available in the Protein Data Bank (PDB: 9JKX for HCAR3, 9JKY for HCAR2) (Ye et al., 2025).

This article expands upon the workflow scenarios and data-backed performance benchmarks discussed in previous reviews by providing molecular-level evidence from recent structural biology advances.

Applications, Limits & Misconceptions

Acifran is optimized for preclinical research on lipid metabolism, metabolic disorders, and signaling pathway elucidation. Its high selectivity reduces confounding effects from off-target GPCR activation. The compound is not intended for clinical, diagnostic, or therapeutic use in humans or animals (APExBIO).

Common Pitfalls or Misconceptions

• Acifran is not a therapeutic or diagnostic agent; its use is restricted to scientific research applications.
• Long-term storage of Acifran in solution leads to loss of activity; fresh preparation is recommended for each experiment (APExBIO).
• It does not activate unrelated GPCRs; selectivity is confined to HCAR2 and HCAR3 (Ye et al., 2025).
• Acifran’s activity profile should not be extrapolated to in vivo efficacy without additional pharmacokinetic data.
• Solubility limits in aqueous buffers must be respected to avoid precipitation and assay variability.

This section updates earlier summaries (incb018424.com) by incorporating precise solubility and storage guidance based on product documentation.

Workflow Integration & Parameters

For optimal results, Acifran should be stored at -20°C and handled under anhydrous conditions. Dissolution in ethanol or DMSO (≤21.82 mg/ml) at room temperature produces a stable stock solution for immediate use. For receptor binding or cAMP assays, use freshly prepared solutions to maintain ≥98.00% purity and receptor specificity. Shipping with blue ice preserves compound integrity during transit (APExBIO).

Acifran’s robust selectivity and reproducible activity profile support advanced lipid signaling workflows, troubleshooting, and mechanistic studies of GPCR modulation as highlighted in related literature. This article clarifies the structural basis and practical handling parameters not covered in earlier overviews.

Conclusion & Outlook

Acifran (SKU B6848) from APExBIO is a benchmark compound for dissecting HCAR2/HCAR3 signaling in lipid metabolism research. Structural and functional data confirm its suitability for selective pathway interrogation at the molecular level (Ye et al., 2025). Continued integration of high-resolution structural information and standardized handling protocols will further advance research into metabolic disorders and lipid-related diseases.